a Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre , Isfahan University of Medical Sciences , Isfahan , Iran.
b Department of Pharmaceutical Chemistry, School of Pharmacy , Isfahan University of Medical Sciences , Isfahan , Iran.
Drug Dev Ind Pharm. 2018 Jul;44(7):1139-1157. doi: 10.1080/03639045.2018.1438462. Epub 2018 Feb 21.
The goal of the present work was to make novel co-polymeric micellar carriers for the delivery of docetaxel (DTX).
Co-polymeric micelles can not only solubilize DTX and eliminate the need for toxic surfactants to dissolve it, but also cause passive targeting of the drug to the tumor and reduce its toxic side effects.
Poly(styrene-maleic acid) (SMA) was conjugated to poly (amide-ether-ester-imide)-poly ethylene glycol (PAEEI-PEG). Copolymer synthesis was proven by Fourier transform infrared (FTIR) and H-nuclear magnetic resonance (H-NMR). The SMA-PAEEI-PEG micelles loaded with DTX were prepared and their critical micelle concentration (CMC), zeta potential, particle size, entrapment efficiency, and their release efficiency were studied. MCF-7 and MDA-MB231 breast cancer cells were used to evaluate the cellular uptake and cytotoxicity of the micelles. The antitumor activity of the DTX-loaded nanomicelles was measured in Balb/c mice.
The FTIR and HNMR spectroscopy confirmed successful conjugation of SMA and PAEEI-PEG. The drug loading efficiency was in the range of 34.01-72.75% and drug release lasted for 120 h. The CMC value of the micelles was affected by the SMA/PAEEI-PEG ratio and was in the range of 29.85-14.28 µg/ml. The DTX-loaded micelles showed five times more cytotoxicity than the free drug. The DTX loaded micelles were more effective in tumor growth suppression in vivo and the animals showed an enhanced rate of survival.
The results show that the SMA-PAEEI-PEG micelles of DTX could potentially provide a suitable parenteral formulation with more stability, higher cytotoxicity, and improved antitumor activity.
本工作的目的是制备新型共聚胶束载体递药系统用于多西他赛(DTX)的给药。
共聚胶束不仅可以增溶 DTX 并消除使用有毒表面活性剂溶解它的需要,而且还可以使药物被动靶向肿瘤并降低其毒副作用。
聚(苯乙烯-马来酸)(SMA)与聚(酰胺-醚-酯-酰亚胺)-聚乙二醇(PAEEI-PEG)相连接。通过傅里叶变换红外(FTIR)和 H 核磁共振(H-NMR)证实共聚合成。制备载有 DTX 的 SMA-PAEEI-PEG 胶束,并研究其临界胶束浓度(CMC)、Zeta 电位、粒径、包封效率及其释放效率。用 MCF-7 和 MDA-MB231 乳腺癌细胞评估胶束的细胞摄取和细胞毒性。在 Balb/c 小鼠中测量载 DTX 纳米胶束的抗肿瘤活性。
FTIR 和 HNMR 光谱证实 SMA 和 PAEEI-PEG 成功连接。药物载药效率在 34.01-72.75%范围内,药物释放持续 120 小时。胶束的 CMC 值受 SMA/PAEEI-PEG 比例的影响,范围在 29.85-14.28μg/ml。载 DTX 的胶束比游离药物的细胞毒性高五倍。载 DTX 的胶束在体内抑制肿瘤生长方面更有效,动物的存活率提高。
结果表明,SMA-PAEEI-PEG 载 DTX 胶束可能为更稳定、更高细胞毒性和改善抗肿瘤活性的合适的注射制剂提供了一种可能性。